All News

Davey B. Daniel, MD, chief medical officer at OneOncology, shares his insights on health equity practices, as well as the importance of developing clinical models within community oncology.

An analysis of more than 500,000 pregnancies over a 15-year period suggests much of the increase in gestational diabetes rates observed during the study period can be attributed to changes in screening practices.

Debra Patt, MD, PhD, MBA, executive vice president at Texas Oncology, discusses financial drivers affecting community oncology as well as new advances within cancer care that allow it to be treated as a chronic disease.

Representatives from Magellan Rx Management provided a detailed overview of current treatment options in ophthalmology and the impact that biosimilars could have during a session at AMCP 2023.

Samyukta Mullangi, MD, MBA, oncology fellow at Memorial Sloan Kettering Cancer Center and incoming medical director at Thyme Care, discussed how the transition to value-based care can contribute to operational and financial risks among oncology practices, and the effectiveness of care navigation platforms in addressing these concerns.

A panel at the Community Oncology Alliance (COA) 2023 Community Oncology Conference highlights the evolution of taking on risk, developing stratification models, and collaborating to learn from fellow providers.

Michael Burger, senior consultant at Point-of-Care Partners, explains that real-time benefit check lets physicians know how much a drug will cost the patient at the time they're writing the prescription, allowing them to give the patient a treatment they know they can afford.

In this AMCP Market Insights session, panelists discussed best practices and challenges when it comes to prescribing antibody drug conjugates, from the payer, provider, and patient perspectives, based on survey findings.

Among these treatments is an aflibercept product with improved dosing for the patient that is coming up for approval in a few months, explained Jeffrey Casberg, senior director of pharmacy at IPD Analytics.

Patients with prostate cancer who were treated with brachytherapy boost showed improved survival compared with those treated with external beam radiotherapy in a recent study.

Minority patients with skin diseases such as psoriasis often experience racial and ethnic barriers to care, a recent review found.

Capitol Hill experts taking part in the Community Oncology Alliance's (COA) Community Oncology Conference said Friday that bipartisan awareness of pharmacy benefit manager (PBM) practices has reached a point that they believe Congress may finally act, if only to require greater transparency.

Associated hospitalization burden could be 2.2 times higher in older adults with respiratory syncytial virus (RSV) than was previously estimated, according to a recent study.

Panelists at the Value-Based Insurance Design Summit discussed research and reforms to address the high cost of medications and the impact it has on equitable access to treatment.

A recent study suggests that sleeve lobectomy is safe to perform in patients with non–small cell lung cancer who received neoadjuvant therapy.

On this episode of Managed Care Cast, we speak with Virginia Wang, PhD, and Matthew L. Maciejewski, PhD, who talk about their recent study on racial disparities in home dialysis, and what more needs to be done to increase uptake and reduce disparities in home dialysis for non-White patients.

The lower number needed to treat suggests that ruxolitinib cream may be more effective for patients with atopic dermatitis (AD), according to a poster presented at AMCP 2023.

People with the inherited disease can expect to live 52.6 years following birth, the report shows.

The Bill & Melinda Gates Medical Research Institute has multiple tuberculosis (TB) therapies and a prophylactic vaccine in development, and its chief medical officer, Michael W. Dunne, MD, remains optimistic long-term about the state of clinical care, especially in low-and-middle-income countries.

Tennessee’s governor rejected $8.8 million in federal grant money for HIV prevention and detection; Senator Bernie Sanders pleads for drug price decrease in his first drug hearing as health chair; the prevalence of autism is growing, with children of color more likely to be diagnosed compared with White children for the first time.

Digital health data can facilitate the participation of underrepresented and diverse patient populations in clinical trials, but first the FDA must build its capability to evaluate such information in its regulatory processes for new drug development.

Actionable ways to implement what is known about social determinants of health were discussed among a panel of experts during a webinar broadcast in the beginning of March.

Both the high-concentration and low-concentration versions of adalimumab-adaz (Hyrimoz) injection will launch in July, along with a wave of other biosimilars to Humira (reference adalimumab).

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Advantages to using surrogate vs clinical end points in drug approvals include earlier access, but there can be concerns about the efficacy and end result of the drug, said Yuqian Liu, PharmD, senior director of specialty clinical solutions at Magellan Rx Management.

Pharmacy benefit manager reform is a major trend in state managed care policy, said Adam Colborn, director of government relations at the Academy of Managed Care Pharmacy (AMCP).

Implementing a strategy that focuses on dose rounding for chemotherapies can have a 3-fold impact of decreasing drug costs, minimizing drug waste, and improving treatment efficiency. This strategy and its benefits were explored in a session on day 2 of AMCP 2023.

A chief concern among those considering the upcoming alternative payment model in oncology, the Enhancing Oncology Model (EOM): Practices will have to take on downside risk immediately.